aTyr Pharma (NASDAQ:LIFE – Get Rating) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Wednesday.

LIFE has been the topic of several other research reports. HC Wainwright lifted their price target on shares of aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, July 21st. Piper Sandler upped their target price on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, aTyr Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $22.75.

aTyr Pharma Trading Down 7.3 %

aTyr Pharma stock traded down $0.27 during trading on Wednesday, reaching $3.42. The company had a trading volume of 128,653 shares, compared to its average volume of 132,376. The firm's 50-day simple moving average is $3.48 and its 200 day simple moving average is $3.82. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10. The firm has a market capitalization of $97.90 million, a price-to-earnings ratio of -2.12 and a beta of 1.49.

Insider Activity

In related news, CEO Sanjay Shukla purchased 15,000 shares of aTyr Pharma stock in a transaction on Friday, July 1st. The shares were bought at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares in the company, valued at approximately $117,498.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.36% of the company's stock.

Hedge Funds Weigh In On aTyr Pharma

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in aTyr Pharma during the second quarter valued at $29,000. D.A. Davidson & CO. purchased a new stake in shares of aTyr Pharma during the 2nd quarter valued at about $31,000. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the 4th quarter valued at about $87,000. Virtu Financial LLC bought a new position in shares of aTyr Pharma in the 1st quarter valued at about $70,000. Finally, Raymond James & Associates bought a new stake in aTyr Pharma during the fourth quarter worth approximately $184,000. Hedge funds and other institutional investors own 65.58% of the company's stock.

aTyr Pharma Company Profile

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Recommended Stories

• Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
• Four Cheap Stocks With Interesting Insider Activity
• Can Health Drink Maker Celsius Outrun Its Monster Rival?
• Is Lyft Going To Make It As Acquisition Rumors Swirl?
• It's Time To Embrace Another 25% Decline In The S&P 500
• Is Five Below Trying to Punch Too High?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.